The options paper suggested a capped special funding program separate from the PBS or a legislative change to enable conditional listings on the PBS. The special funding program would be more straightforward and timely. …
A simple, timely option for a 'bridging fund' that can fit within the existing legal framework
July 10, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Bristol Myers Squibb Australia riders more than double their target for Rare Cancers Australia
November 10, 2026 - - Latest News -
Dispatch AI Index finds routine AI use but questions over governance
November 10, 2026 - - News of the Day -
Mayne Pharma sells Salisbury business to Evaris Pharma for $55.5 million
November 10, 2026 - - Latest News -
Pfizer commissioned polling finds strong public support for investing in the PBS
November 9, 2026 - - Latest News -
Pfizer confirms Ben Fitzsimmons as Australia and New Zealand chief
November 9, 2026 - - Latest News -
Coalition edges ahead in New Zealand as Stephenson returns and Pharmac pledges await the 'specials'
November 9, 2026 - - Latest News -
Celairis launches with plan to end the region's place at the rear of the launch queue
November 9, 2026 -